PolarityTE Inc

PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. PolarityTE was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RegenETP, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm's products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. It was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

SALT LAKE CITY, Oct. 7, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided an update regarding its Investigational New Drug Application (IND) for SkinTE® with a proposed indication for chronic cutaneous ulcers submitted to the Food and Drug Administration (FDA) in July 2021.   The Company received the clinical hold letter from FDA by the previously announced date of September 21, 2021.

PolarityTE Provides Update on Investigational New Drug Application

NEW YORK, Oct. 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the "Class Period"), of the important November 23, 2021 lead plaintiff deadline. SO WHAT: If you purchased PolarityTE securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED LAW FIRM, Encourages PolarityTE, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - PTE

New York, New York--(Newsfile Corp. - October 1, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no...

PTE Shareholder Alert: Rosen, Recognized Investor Counsel, Encourages PolarityTE, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PTE

NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against PolarityTE, Inc.  ("PolarityTE" or the "Company") (NASDAQ: PTE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, inclusive (the "Class Period").

PTE Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies PolarityTE, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the "Class Period").

PTE INVESTOR NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PolarityTE, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PTE

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) in the United States District Court for the District of Utah on behalf of all persons and entities who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the “Class Period”). Investors have unt

POLARITYTE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 23, 2021. SO WHAT: If you purchased PolarityTE securities during the Class Period y

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages PolarityTE, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PTE

NEW YORK, Sept. 24, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) and certain of its officers.

Pomerantz Law Firm Announces the Filing of a Class Action Against PolarityTE, Inc. and Certain Officers - PTE

The heavy selling pressure might have exhausted for PolarityTE, Inc. (PTE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 18.2% in 4 Weeks, Here's Why PolarityTE, Inc. (PTE) Looks Ripe for a Turnaround

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021 and participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021. A live audio webcast of the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021 at 7:00 a

PolarityTE to Attend H.C. Wainwright 23rd Annual Global Investment Conference and 2021 Cantor Virtual Global Healthcare Conference

NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PolarityTE, Inc. - PTE

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Richard Hague as Chief Executive Officer, the election of David Seaburg to the Board of Directors, and the appointment of Ryan Mathis, MD, as Chief Medical Officer. Mr. Hague joined the Company in April 2019 as Chief Operating Officer and served in the Office of the Chief Executive beginning in August 2019 until April 2020, when he began serving as the Company's President in addition to Chief Oper

PolarityTE Appoints Richard Hague as Chief Executive Officer and Elects David Seaburg to Board of Directors and Chair of Strategic Review Committee

The FDA has issued a clinical hold on PolarityTE Inc's (NASDAQ: PTE) SkinTE Investigational New Drug Application (IND) for chronic cutaneous ulcers. The FDA provided feedback on certain Chemistry, Manufacturing, and Control (CMC) items that need to be addressed before proceeding with a pivotal study.

PolarityTE Stock Drops On FDA Clinical Hold On SkinTE Trial Application

PolarityTE (PTE) stock is taking a beating on Tuesday after the biotechnology company got an update from the FDA on its IND. The post PTE Stock: The FDA News That Has Biotech Penny Stock PolarityTE Plunging Today appeared first on InvestorPlace.

PTE Stock: The FDA News That Has Biotech Penny Stock PolarityTE Plunging Today

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided an update regarding correspondence from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) for SkinTE® with a proposed indication for chronic cutaneous ulcers, which was filed on July 23, 2021. The FDA provided feedback that certain Chemistry, Manufacturing, and Control (CMC) items nee

PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®

PolarityTE, Inc. (PTE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About PolarityTE, Inc. (PTE) Rating Upgrade to Buy

PolarityTE's (PTE) CEO David Seaburg on Q2 2021 Results - Earnings Call Transcript

PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of 50.00% and -16.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

PolarityTE, Inc. (PTE) Reports Q2 Loss, Lags Revenue Estimates

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the second quarter ended June 30, 2021. Recent Business Updates Submitted an Investigational New Drug application (IND) for SkinTE® on July 23, 2021, for the proposed indication of treatment of chronic cutaneous ulcers Reported SkinTE met primary and secondary endpoints in final anal

PolarityTE Reports Second Quarter Financial Results and Provides Business Update

PolarityTE, Inc. (PTE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PolarityTE, Inc. (PTE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended June 30, 2021 by press release on Thursday, August 12, 2021 at approximately 4:00 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on August 12, 2021 at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-581-5838 (U.S. and Canada) or +44 (0)330 336 9104 (International) with confirmation code 21

PolarityTE to Report Second Quarter Financial Results on August 12, 2021

PolarityTE Inc (NASDAQ: PTE) has announced final data from a trial evaluating SkinTE plus standard of care (SOC) vs. SOC alone for Diabetic Foot Ulcers.

PolarityTE's SkinTE Meets Primary, Secondary Endpoint Goals In Diabetic Foot Ulcer Trial

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced final data from a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers (DFU) with its investigational product SkinTE® plus standard of care (SOC) vs SOC alone (NCT03881254). The trial met the primary endpoint of wound closure at 12 weeks and secondary endpoint of Percent Area Reduction (PAR) assessed at 4, 6, 8, 10, and 12 weeks. 100 participants were evaluated across 13 sites with 5

SkinTE® Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer Trial

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced the submission of an investigational new drug application (IND) to the United States Food and Drug Administration (FDA) seeking authorization to commence a clinical trial to evaluate its SkinTE product for the proposed indication of treatment of chronic cutaneous ulcers. SkinTE is PolarityTE's human cellular and tissue-based product derived from a patient's own skin. PolarityTE included in its IND submission data ac

PolarityTE Submits Investigational New Drug Application for SkinTE® in Chronic Cutaneous Ulcers

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) is issuing the following statement: Based on investor inquiries, it has been brought to the attention of PolarityTE that there may be confusion amongst the investment community related to PolarityTE's stock and Peet DeFi, which is a crypto currency asset, and the Company is concerned that such confusion may have affected trading in PolarityTE stock. This press release serves to inform investors that PolarityTE, traded on the Nasdaq

News for PolarityTE Inc Stock (PTE)